跳至主要内容
临床试验/NCT03284320
NCT03284320已完成不适用

Retrospective Study to Evaluate Efficacy and Safety of Trabectedin (Yondelis®) in Sarcoma Patients

University Medicine Greifswald1 个研究点 分布在 1 个国家目标入组 514 人开始时间: 2017年4月18日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
514
试验地点
1
主要终点
- Progression free survival (PFS)

研究概览

简要总结

The objectives of this trial is to evaluate efficacy and safety of treatment with Trabectedin in a large cohort of German patients with soft tissue and bone sarcomas.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with histologically confirmed soft tissue or bone sarcomas treated with at least one cycle of Trabectedin in any line of therapy.
  • Age ≥18years at start of therapy with Trabectedin
  • Informed Consent
  • Patients already deceased may be included when the treating physician is able to determine the presumptive consent

排除标准

  • No follow-up data available

结局指标

主要结局

- Progression free survival (PFS)

时间窗: At the time of every treatment documentation up to the end of treatment, approximately 2 years

- Overall survival (OS)

时间窗: At the time of every treatment documentation up to the end of treatment, approximately 2 years

次要结局

  • CTCAE (Common Terminology Criteria for Adverse Events) 4.03(At the time of every treatment documentation up to the end of treatment, approximately 2 years)

研究者

发起方
University Medicine Greifswald
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验